Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2017 May 19;66(19):509-513.
doi: 10.15585/mmwr.mm6619a6.

Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016

Monica E Patton, David Stephens, Kelly Moore, Jessica R MacNeil
Practice Guideline

Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016

Monica E Patton et al. MMWR Morb Mortal Wkly Rep. .

Abstract

Two serogroup B meningococcal (MenB) vaccines are currently licensed for use in persons aged 10-25 years in the United States. The two vaccines are MenB-FHbp (Trumenba, Pfizer, Inc.) (1) and MenB-4C (Bexsero, GlaxoSmithKline Biologicals, Inc.) (2). In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended use of MenB vaccines among certain groups of persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease* (Category A) (3), and in June 2015, ACIP recommended that adolescents and young adults aged 16-23 years may be vaccinated with MenB vaccines to provide short-term protection against most strains of serogroup B meningococcal disease (Category B†) (4). Consistent with the original Food and Drug Administration (FDA) licensure for the two available MenB vaccines, ACIP recommended either a 3-dose series of MenB-FHbp or a 2-dose series of MenB-4C. Either MenB vaccine can be used when indicated; ACIP does not state a product preference. The two MenB vaccines are not interchangeable; the same vaccine product must be used for all doses in a series. In April 2016, changes to the dosage and administration of MenB-FHbp were approved by FDA to allow for both a 2-dose series (administered at 0 and 6 months) and a 3-dose series (administered at 0, 1-2, and 6 months) (5,6). In addition, the package insert now states that the choice of dosing schedule depends on the patient's risk for exposure and susceptibility to serogroup B meningococcal disease. These recommendations are regarding use of the 2- and 3-dose schedules of MenB-FHbp vaccine (Trumenba) and replace previous ACIP recommendations for use of MenB-FHbp vaccine published in 2015 (3,4). Recommendations regarding use of MenB-4C (Bexsero) are unchanged (3,4).

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Persistence of hSBA responses ≥1:4 against four selected serogroup B meningococcal strains in subjects aged 11–18 years, up to 48 months (m) after completion of a 2-dose (0, 6 months) or 3-dose (0, 2, 6 months) series of MenB-FHbp Abbreviation: hSBA = serum bactericidal antibody activity, measured using human complement. * Expressed as a percentage, with error bars representing 95% confidence intervals. † Serogroup B meningococcal strains expressing FHbp (factor H binding protein) of subfamily A (A22, A56) or subfamily B (B24, B44). § Number of subjects for persistence time points: 0, 6 m = 99–116; 0, 2, 6 m = 92–114.
FIGURE 2
FIGURE 2
Persistence of hSBA responses ≥1:4 and GMTs against four selected serogroup B meningococcal strains at 48 months (m) in subjects aged 11–18 years after completion of a 2-dose (0, 6 months) or 3-dose (0, 2, 6 months) series of MenB-FHbp, and hSBA responses ≥1:4 and GMTs to a booster dose of MenB-FHbp at approximately 48 months after primary vaccination Abbreviations: GMTs = geometric mean antibody titers; hSBA = serum bactericidal antibody activity, measured using human complement. * Expressed as a percentage, with error bars representing 95% confidence intervals. † GMTs were as follows. A22 (0, 6 m): Pre 6.4, 1m post primary 55.8, 48m post primary 15.3, 1m post booster 140.0; (0, 2, 6m): Pre 6.3, 1m post primary 59.5, 48m post primary 15.4, 1m post booster 119.1. A56 (0, 6m): Pre 6.7, 1m post primary 143.1, 48m post primary 15.8, 1m post booster 358.0; (0, 2, 6m): Pre 6.1, 1m post primary 191.2, 48m post primary 17.4, 1m post booster 370.8. B24 (0, 6m): Pre 5.0, 1m post primary 29.2, 48m post primary 7.8, 1m post booster 86.0; (0, 2, 6m): Pre 5.1, 1m post primary 30.5, 48m post primary 9.1, 1m post booster 80.3. B44 (0, 6m): Pre 4.5, 1m post primary 35.5, 48m post primary 5.3, 1m post booster 84.6; (0, 2, 6m): Pre 4.5, 1m post primary 50.2, 48m post primary 5.3, 1m post booster 117.6. § Serogroup B meningococcal strains expressing FHbp (factor H binding protein) of subfamily A (A22, A56) or subfamily B (B24, B44). Number of subjects for persistence time points: 0, 6 m = 58–62; 0, 2, 6 m = 57–58.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McNeil LK, Zagursky RJ, Lin SL, et al. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev 2013;77:234–52. 10.1128/MMBR.00056-12 - DOI - PMC - PubMed
    1. Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 2012;30(Suppl 2):B87–97. 10.1016/j.vaccine.2012.01.033 - DOI - PMC - PubMed
    1. Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015;64:608–12. - PMC - PubMed
    1. MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015;64:1171–6. 10.15585/mmwr.mm6441a3 - DOI - PubMed
    1. Food and Drug Administration. Summary basis for regulatory action. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2016. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedPr...

Publication types

Substances